Neos Therapeutics, Inc. (NEOS) Financial Statements (2024 and earlier)
Company Profile
Business Address |
2940 N. HIGHWAY 360 GRAND PRAIRIE, TX 75050 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
9/30/2020 MRQ | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
Current Assets | ||||||||
Cash, cash equivalents, and short-term investments | 24,894 | 46,478 | 50,417 | 39,782 | 90,763 | |||
Cash and cash equivalents | 16,830 | 46,478 | 31,969 | 24,352 | 90,763 | |||
Short-term investments | 8,064 | 18,448 | 15,430 | |||||
Receivables | 26,563 | 27,801 | 13,671 | 6,135 | 3,903 | |||
Inventory, net of allowances, customer advances and progress billings | 11,010 | 10,367 | 13,459 | 5,767 | 2,520 | |||
Inventory | 11,010 | 10,367 | 13,459 | 5,767 | 2,520 | |||
Other current assets | 4,032 | 5,093 | 2,865 | 1,058 | ||||
Other undisclosed current assets | 4,092 | 720 | ||||||
Total current assets: | 66,559 | 88,678 | 82,640 | 55,269 | 98,244 | |||
Noncurrent Assets | ||||||||
Operating lease, right-of-use asset | 3,044 | ✕ | ✕ | ✕ | ✕ | |||
Property, plant and equipment | 7,345 | 7,914 | 8,203 | 7,076 | 5,124 | |||
Intangible assets, net (including goodwill) | 12,543 | 14,616 | 16,348 | 15,579 | 16,672 | |||
Intangible assets, net (excluding goodwill) | 12,543 | 14,616 | 16,348 | 15,579 | 16,672 | |||
Other noncurrent assets | 1,382 | 149 | 162 | 2,218 | 2,470 | |||
Total noncurrent assets: | 24,314 | 22,679 | 24,713 | 24,873 | 24,266 | |||
TOTAL ASSETS: | 90,873 | 111,357 | 107,353 | 80,142 | 122,510 | |||
LIABILITIES AND EQUITY | ||||||||
Liabilities | ||||||||
Current Liabilities | ||||||||
Accounts payable and accrued liabilities | 46,838 | 48,548 | 22,030 | 13,062 | 7,965 | |||
Accounts payable | 6,650 | 12,730 | 11,460 | 7,798 | 4,824 | |||
Accrued liabilities | 40,188 | 35,818 | 10,570 | 5,264 | 3,141 | |||
Debt | 1,517 | 8,557 | 896 | 4,921 | 7,973 | |||
Deferred revenue and credits | ✕ | ✕ | ✕ | 14,676 | 3,662 | |||
Other undisclosed current liabilities | 15,000 | |||||||
Total current liabilities: | 63,355 | 57,105 | 37,602 | 21,645 | 15,938 | |||
Noncurrent Liabilities | ||||||||
Long-term debt and lease obligation, including: | 3,585 | 43,217 | 58,938 | 58,599 | 26,271 | |||
Finance lease, liability | 331 | ✕ | ✕ | ✕ | ✕ | |||
Other undisclosed long-term debt and lease obligation | 43,217 | 58,938 | 58,599 | 26,271 | ||||
Liabilities, other than long-term debt | 1,295 | 3,190 | 2,923 | 1,406 | 1,380 | |||
Deferred revenue and credits | ✕ | ✕ | ✕ | 1,083 | 1,174 | 1,166 | ||
Deferred rent credit | 989 | ✕ | ✕ | ✕ | ||||
Other liabilities | 160 | 184 | 180 | |||||
Operating lease, liability | 3,254 | ✕ | ✕ | ✕ | ✕ | |||
Business combination, contingent consideration, liability | 232 | 214 | ||||||
Derivative instruments and hedges, liabilities | 1,135 | 2,017 | 1,660 | |||||
Other undisclosed noncurrent liabilities | 28,768 | 40 | 547 | |||||
Total noncurrent liabilities: | 33,648 | 46,407 | 61,861 | 60,045 | 28,198 | |||
Total liabilities: | 97,003 | 103,512 | 99,463 | 81,690 | 44,136 | |||
Equity | ||||||||
Equity, attributable to parent | (6,130) | 7,845 | 7,890 | (1,548) | 78,374 | |||
Common stock | 50 | 50 | 29 | 16 | 16 | |||
Treasury stock, value | (352) | (352) | (352) | (232) | (171) | |||
Additional paid in capital | 328,056 | 325,130 | 274,584 | 198,787 | 195,314 | |||
Accumulated other comprehensive income (loss) | 1 | (6) | (1) | |||||
Accumulated deficit | (333,885) | (316,983) | (266,365) | (200,118) | (116,785) | |||
Total equity: | (6,130) | 7,845 | 7,890 | (1,548) | 78,374 | |||
TOTAL LIABILITIES AND EQUITY: | 90,873 | 111,357 | 107,353 | 80,142 | 122,510 |
Income Statement (P&L) ($ in thousands)
9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
---|---|---|---|---|---|---|---|
Revenues | 64,649 | 49,988 | 25,018 | 9,154 | 3,792 | ||
Revenue, net | ✕ | ✕ | ✕ | 25,018 | 9,154 | 3,792 | |
Cost of revenue (Cost of Goods and Services Sold) | (25,123) | (26,928) | (12,391) | (11,437) | (5,547) | ||
Gross profit: | 39,526 | 23,060 | 12,627 | (2,283) | (1,755) | ||
Operating expenses | (49,941) | (66,556) | (69,643) | (74,123) | (24,823) | ||
Operating loss: | (10,415) | (43,496) | (57,016) | (76,406) | (26,578) | ||
Nonoperating income (Other Nonoperating income) | 1,533 | 795 | 854 | 1,215 | 831 | ||
Interest and debt expense | (8,009) | (8,974) | (1,187) | (576) | |||
Loss from continuing operations before income taxes: | (16,891) | (51,675) | (56,162) | (76,378) | (26,323) | ||
Income tax expense | (11) | ||||||
Loss from continuing operations: | (16,902) | (51,675) | (56,162) | (76,378) | (26,323) | ||
Loss before gain (loss) on sale of properties: | ✕ | (16,902) | (51,675) | (56,162) | (76,378) | (26,323) | |
Other undisclosed net loss | (10,085) | ||||||
Net loss: | (16,902) | (51,675) | (66,247) | (76,378) | (26,323) | ||
Other undisclosed net loss attributable to parent | (6,955) | (4,458) | |||||
Net loss attributable to parent: | (16,902) | (51,675) | (66,247) | (83,333) | (30,781) | ||
Preferred stock dividends and other adjustments | (2,390) | ||||||
Net loss available to common stockholders, diluted: | (16,902) | (51,675) | (66,247) | (83,333) | (33,171) |
Comprehensive Income ($ in thousands)
9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
---|---|---|---|---|---|---|---|
Net loss: | (16,902) | (51,675) | (66,247) | (76,378) | (26,323) | ||
Comprehensive loss: | (16,902) | (51,675) | (66,247) | (76,378) | (26,323) | ||
Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 1 | 6 | (5) | (6,956) | |||
Comprehensive loss, net of tax, attributable to parent: | (16,901) | (51,669) | (66,252) | (83,334) | (26,323) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.